Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00434)
Name
Miglustat
Synonyms    Click to Show/Hide the Synonyms of This API
Miglustat; N-Butyldeoxynojirimycin; 72599-27-0; Zavesca; N-Butylmoranoline; NB-DNJ; N-butyl-1-deoxynojirimycin; (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol; n-Butyl deoxynojirimycin; Butyldeoxynojirimycin; N-(n-Butyl)deoxynojirimycin; SC-48334; OGT 918; N-Butyl-DNJ; SC 48334; UNII-ADN3S497AZ; 3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R,3r,4R,5S)-; OGT-918; ADN3S497AZ; CHEMBL1029; CHEBI:50381; 72599-27-0 (free base); n-Butyl dnj; MFCD00272581; DSSTox_CID_25618; DSSTox_RID_81006; DSSTox_GSID_45618; miglustatum; Vevesca; Zavesca (TN); CAS-72599-27-0; N-Bu-DNJ; N-Butyl-deoxynojirimycin; SC48334; Brazaves; Miglustat [USAN:INN:BAN]; D-Glucitol, 1,5-(butylimino)-1,5-dideoxy-; NCGC00018140-02; Brazaves (TN); 1,5-Dideoxy-1,5-N-butylimino-D-glucitol; N-(n-butyl)-1,5-dideoxy-1,5-imino-D-glucitol; Miglustat (JAN/USAN/INN); SCHEMBL246893; GTPL4841; DTXSID6045618; BDBM18355; HMS2090N20; ZINC3794711; Tox21_110830; 3917AH; AKOS028109118; Tox21_110830_1; ACN-025888; DB00419; SB18741; 3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha,5beta))-; NCGC00024452-03; NCGC00024452-04; HY-17020; N-(n-Butyl)-1-deoxynojirimycin min. 99%; N-Butyldeoxynojirimycin, film (dried in situ); D05032; AB00489939-10; Q425911; SR-01000000043; SR-01000000043-2; W-203639; 134282-77-2
Clinical Status
Approved
Disease Indication Gaucher disease ICD-11: 5C56 [1]
PubChem CID
51634
Formula
C10H21NO4
Canonical SMILES
CCCCN1C[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O
InChI
1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1
InChIKey
UQRORFVVSGFNRO-UTINFBMNSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=51634"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 219.28 Topological Polar Surface Area 84.2
XlogP -0.6 Complexity 190
Heavy Atom Count 15 Rotatable Bond Count 4
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 5
Full List of Drug Formulations (DFMs) Containing This API
          Miglustat 100 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Ferrosoferric oxide; Titanium dioxide; Povidone k30; Gelatin, unspecified; Shellac; Sodium starch glycolate type a potato
                   Dosage Form Oral Capsule
                   Company CoTherix
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [2]
References
1 FDA label for approved miglustat from the official website of the U.S. Food and Drug Administration.
2 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.